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total, with COPD, of all stages, who were hospitalized in the
pneumonology department, in 2006 and 2007. The analysis was
performed retrospectively. Information on mean treatment cost
per patient is presented separately for the I-IV COPD stages,
according to GOLD criteria. Direct cost analysis was based on
cost of personnel of the clinic, medication, laboratory and imaging
tests. The economic analysis did not include the depreciation of
capital assets as well as the overhead cost. The prices used for the
analysis were based on Greek NHS prices (FEK157/91, A’ issue),
2006 Euros. RESULTS: The mean (SD) length of stay in the
deparment of pneumonology for a COPD patient was 6 (4) days
and the mean(SD) actual cost per patient with stage I COPD was
€1091 (85), the mean cost for a patient with stage II COPD was
estimated at €1081 (106.5) for the thewhole length of stay and the
mean cost for stage III and IVCOPDpatients are 1146 (120,3) and
€1222 (197), respectively. CONCLUSIONS: COPD posses a con-
siderable economic burden to health care systems and societies.
These ﬁndings are in accordance to international literature.
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OBJECTIVES: Assessment of direct and indirect costs of COPD
exacerbations under usual clinical practice in primary and second-
ary care from societal perspective in Poland METHODS: An
observational, prospective study was conducted among patients
with exacerbation of moderate or severe COPD. All patients
(n = 197) were divided into two groups depending on place of
care. The group treated in hospital care (HC) and in ambulatory
care (AC) adequatly oconsisted of 89 and 108 patients. The direct
costs included cost of drugs, diagnostic tests, inhospital and
outpatient care.We singled out one-day medical treatment facility
costs for inpatients. The indirect costs included costs of work days
lost. RESULTS: The mean duration of COPD exacerbation did
not differ signiﬁcantly between the groups (p > 0.5, adaquately
9.5 and 8.8 days for HC and AC group). The total health care cost
per exacerbation was €1410,0 (5078.50 PLN) in secondary care
(the HC group) and it was 10.5 times higher than the total cost of
exacerbation in primary care (the AC group) €134,3 (483.80
PLN) (according to course of currencies on 15 December 2007).
The costs of drugs and diagnostic tests were signiﬁcantly higher in
the HC group than in the AC group, however it were facility costs
of inhospital stay and medical visits in the HC group that inﬂu-
enced expenditures related to COPD exacerbations most tremen-
dously, as they were 27 times higher than in the AC group.
CONCLUSIONS: In Poland the costs of COPD exacerbation
managed in secondary care are 10.5-fold higher than in primary
care. Therefore, the decisions about admission of patients with
COPD exacerbation to hospital should be made carefully.
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OBJECTIVES: To estimate differences in total payments for
treatment and resource utilization among patients with COPD
over a one-year period following initiation of treatment with
albuterol MDI (ALB) or levalbuterol MDI (LEV) in usual prac-
tice in the United States. METHODS: MarketScan® data were
used to identify 46,454 COPD patients age > 5 who ﬁlled a new
prescription for ALB or LEV between October 1, 2003 through
September 30, 2006 and met other study inclusion/exclusion
criteria. Multivariate methods were used to adjust for differences
in potential confounders across treatment groups, such as patient
age, gender, COPD severity score, Charlson comorbidity score,
prescribing physician specialty, patterns of other respiratory drug
use, and geographic region. Given the eminent ban (effective
January 1, 2009) on MDIs using CFC propellant, in addition to
actual claims payments, hypothetical “HFA-propellant-only”
claims payments, calculated by replacing payment rates for CFC
drugs with payment rates for HFA versions of the same drugs,
also are analyzed to enhance the applicability of study results
to the post-CFC environment. RESULTS: Total payments for
LEV patients were $2769 higher (p < 0.001) compared to ALB
patients. Total payments for LEV patients were $2467 higher
(p < 0.001) than hypothetical ALB-HFA-only patients. Payments
for respiratory drugs were higher for LEV patients ($673,
p < 0.001; projected HFA-only payments $515; p < 0.001).
There was no statistically signiﬁcant difference between ALB and
LEV patients in risk of hospitalization (OR = 1.033, p = 0.56)
or frequency of ED visits (IRR = 0.99, p = 0.80). However,
LEV patients had a higher frequency of total outpatient visits
(IRR = 1.13, p < 0.001) and COPD-related outpatient visits
(IRR = 1.17, p < 0.001). CONCLUSIONS: COPD patients using
LEV had higher total payments and respiratory drug payments
compared to ALB patients. LEV patients had more frequent
outpatient visits. There was no consistent, statistically signiﬁcant
association between treatment and either likelihood or frequency
of hospitalization or ED visits.
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OBJECTIVES: To measure relative rates of discontinuation
among commonly prescribed chronic disease medication classes
under conditions of routine care. METHODS: De-identiﬁed
pharmacy records for 1.99 million patients who received medi-
cation from retail pharmacy chains throughout the United States
were used to select patients who obtained a ﬁll between January
1, 2007 and January 30, 2007 for any of the following medica-
tion classes: antidepressants (n = 339,059); bisphosphonates
(n = 120,098); cardiovascular agents (n = 622,947); glaucoma
medications (n = 48,229); statins (n = 452,978); inhaled steroids
(n = 95,900); insulins (n = 66,637); and oral antidiabetic agents
(n = 248,280). The primary outcome measure was the median
time-to-discontinuation (TD50). Kaplan-Meier analysis was used
to estimate the risk of discontinuation over the subsequent 360
days for both “inexperienced” and “experienced” groups of
patients. Inexperienced patients were deﬁned as those who had
not been dispensed an in-class medication in the prior 180 days;
experienced patients were those who had been. Discontinuation
was deﬁned as being 30 days late for a scheduled reﬁll. Patients
switched to an in-class medication were considered to have
continued therapy. RESULTS: Median days to discontinuation
(TD50) among patients who had not ﬁlled a prescription for an
in-class medication in the prior 180 days were: inhaled steroids
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